Synereca Pharmaceuticals, an Oklahoma City-based biopharmaceutical company focused on increasing the effectiveness of antibiotics, raised $600k in funding.
The round was led by Accele Venture Partners, the investing arm of life sciences accelerator Accele Biopharma, the Oklahoma Seed Capital Fund, managed by i2E, Inc., and other existing investors.
The company, which has now received $2.5m, intends to use the funds for the development of compounds that address bacterial resistance to current antibiotics.
Led by Clayton Duncan, CEO, Synereca Pharmaceuticals develops novel compounds that show promise in enhancing the effectiveness of existing antibiotics against drug-resistant Gram-Negative bacteria that cause hundreds of thousands of hospital-acquired infections each year.
Preclinical results have shown that combining the company’s compounds with current antibiotics restores and enhances their activity against resistant pathogens that cause difficult-to-treat bacterial infections.
Synereca is a portfolio company of Accele Biopharma, an Oklahoma City-based biotechnology accelerator. It also has laboratories in OKC and North Carolina.